Javier Kattan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Javier Kattan has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Toso
Pontificia Universidad Católica de Chile
2 shared publications Matías Luco
Department of Neonatology, Pontificia Universidad Católica de Chile, Division of Pediatrics, School of Medicine, Santiago, Chile
2 shared publications- Aixa Reusmann
Department of Pediatric Surgery, Juan P. Garrahan National Pediatric Hospital, Buenos Aires Autonomous City, Argentina; Department of Pediatric Surgery, Germans Trias I Pujol Hospital, Generalitat de Catalunya, Badalona, Spain
1 shared publication Alberto Toso
Department of Neonatology, Pontificia Universidad Catolica de Chile, Santiago, Chile
1 shared publicationAlejandro Zavala
Pontificia Univ Catolica Chile, Sch Med, Surg Div, Pediat Surg Sect, Lira 40, Santiago, Chile
1 shared publication- Andrea I. Moreno Switt
Escuela de Medicina Veterinaria, Facultad de Agronomía y Sistemas Naturales, Facultad de Medicina y Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile
1 shared publication
Latest Publications
- Open Access
- 13 April 2026
- Published by Ubiquity Press, Ltd. in Annals of Global Health
- Vol. 92 (1)
From Excellent Clinicians to Custodians of Life: Reimagining Internationalization in Health Professions Education
Health professions education faces growing challenges such as climate disruption, migration, inequities, and information-driven mistrust. Preparing health professionals for this reality requires more than clinical excellence; it calls for reimagining internationalization as the intentional integration of global, intercultural, ethical, interprofessional, and ecological competencies across curricula and accreditation systems. This commentary argues that internationalization must move beyond mobility for a privileged few toward a universal framework of global competencies accessible to all students. Drawing on frameworks from UNESCO, World Health Organization, and the Lancet Commission, and illustrated through the experience of the Faculty of Medicine at Pontificia Universidad Católica de Chile, it outlines three strategic directions: reorienting accreditation, embedding global engagement into curricula, and fostering authentic interdisciplinary teamwork. Ultimately, this paper offers a normative framework and institutional illustration to guide faculties of health worldwide in preparing graduates as custodians of life in a shared and fragile world.
- 13 April 2026
- Published by Ubiquity Press, Ltd. in Annals of Global Health
- Vol. 92 (1)
Open AccessFrom Excellent Clinicians to Custodians of Life: Reimagining Internationalization in Health Professions Education
Health professions education faces growing challenges such as climate disruption, migration, inequities, and information-driven mistrust. Preparing health professionals for this reality requires more than clinical excellence; it calls for reimagining internationalization as the intentional integration of global, intercultural, ethical, interprofessional, and ecological competencies across curricula and accreditation systems. This commentary argues that internationalization must move beyond mobility for a privileged few toward a universal framework of global competencies accessible to all students. Drawing on frameworks from UNESCO, World Health Organization, and the Lancet Commission, and illustrated through the experience of the Faculty of Medicine at Pontificia Universidad Católica de Chile, it outlines three strategic directions: reorienting accreditation, embedding global engagement into curricula, and fostering authentic interdisciplinary teamwork. Ultimately, this paper offers a normative framework and institutional illustration to guide faculties of health worldwide in preparing graduates as custodians of life in a shared and fragile world.
- 4 July 2024
- Published by Springer Nature in Journal of Perinatology
- Vol. 44 (10) , 1448-1453
Vasopressin as adjunctive therapy in pulmonary hypertension associated with refractory systemic hypotension in term newborns
Objective The use of vasopressin as an adjunctive therapy in pulmonary hypertension associated with refractory systemic hypotension has increased. The objective of our study is to describe its effects on term infants. Study design Retrospective observational study. Setting in a referral level IV neonatal intensive care unit from a middle-income region. The patients are term neonates admitted to our NICU who required vasopressin due to severe Pulmonary Hypertension and refractory hypotension during a 49-month period (December 2019 and December 2023). Results We identified 68 term infants, all in mechanical ventilation, receiving inhaled nitric oxide (iNO), and a phased protocol management for hypotension. Vasopressin was a started at a mean of 2 days with a mean duration of 80 h. Regarding hemodynamic outcome: diastolic, systolic, and median systemic pressure significantly increased during the first 4 h of treatment, as well as arterial pH and urine output. Accordingly, lactate and Vasoactive Inotropic Score (VIS) score decreased after 4 and 8 h, respectively, after vasopressin was started. Regarding oxygenation markers: oxygen requirements and mean airway pressure decreased significantly (and therefore the oxygenation index decreased in concordance) after 4 h of vasopressin. Echocardiographic indices of pulmonary hypertension progressively improved after vasopressin infusion with a significant decrease of tricuspid ingurgitation velocities and the rate of right-to- left ductal shunt through the ductus arteriosus. In the same way, left and right ventricular output increased after the initiation of vasopressin. Conclusion This study showed that the use of vasopressin in neonates with persistent pulmonary hypertension was associated with a rapid and significant improvement in oxygenation and hemodynamic markers of perfusion, including blood pressure. Its effects begin early during the first hours of treatment.
- 4 July 2024
- Published by Springer Nature in Journal of Perinatology
- Vol. 44 (10) , 1448-1453
Vasopressin as adjunctive therapy in pulmonary hypertension associated with refractory systemic hypotension in term newborns
Objective The use of vasopressin as an adjunctive therapy in pulmonary hypertension associated with refractory systemic hypotension has increased. The objective of our study is to describe its effects on term infants. Study design Retrospective observational study. Setting in a referral level IV neonatal intensive care unit from a middle-income region. The patients are term neonates admitted to our NICU who required vasopressin due to severe Pulmonary Hypertension and refractory hypotension during a 49-month period (December 2019 and December 2023). Results We identified 68 term infants, all in mechanical ventilation, receiving inhaled nitric oxide (iNO), and a phased protocol management for hypotension. Vasopressin was a started at a mean of 2 days with a mean duration of 80 h. Regarding hemodynamic outcome: diastolic, systolic, and median systemic pressure significantly increased during the first 4 h of treatment, as well as arterial pH and urine output. Accordingly, lactate and Vasoactive Inotropic Score (VIS) score decreased after 4 and 8 h, respectively, after vasopressin was started. Regarding oxygenation markers: oxygen requirements and mean airway pressure decreased significantly (and therefore the oxygenation index decreased in concordance) after 4 h of vasopressin. Echocardiographic indices of pulmonary hypertension progressively improved after vasopressin infusion with a significant decrease of tricuspid ingurgitation velocities and the rate of right-to- left ductal shunt through the ductus arteriosus. In the same way, left and right ventricular output increased after the initiation of vasopressin. Conclusion This study showed that the use of vasopressin in neonates with persistent pulmonary hypertension was associated with a rapid and significant improvement in oxygenation and hemodynamic markers of perfusion, including blood pressure. Its effects begin early during the first hours of treatment.
- 15 February 2023
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 58 (7) , 1230-1234
Risk-stratified Results among Congenital Diaphragmatic Hernia Patients in Two Large Extracorporeal Membrane Oxygenation Centers in South America
- 15 February 2023
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 58 (7) , 1230-1234
Risk-stratified Results among Congenital Diaphragmatic Hernia Patients in Two Large Extracorporeal Membrane Oxygenation Centers in South America
- Open Access
- 23 November 2022
- Published by Springer Nature in Pediatric Research
- Vol. 95 (4) , 941-948
Congenital diaphragmatic hernia: phosphodiesterase-5 and Arginase inhibitors prevent pulmonary vascular hypoplasia in rat lungs
Background Severe pulmonary hypoplasia related to congenital diaphragmatic hernia (CDH) continues to be a potentially fatal condition despite advanced postnatal management strategies. Objective To evaluate the effect of the antenatal sildenafil and 2(S)-amino-6-boronohexanoic acid (ABH-Arginase inhibitor) on lung volume, pulmonary vascular development, and nitric oxide (NO) synthesis in a Nitrofen-induced CDH rat model. Methods Nitrofen-induced CDH rat model was used. Nitrofen was administrated on embryonic day(E) 9,5. At E14, five intervention groups were treated separately: Nitrofen, Nitrofen+Sildenafil, Nitrofen+ABH, Nitrofen+Sildenafil+ABH and Control. At term, offspring’s lungs were weighed, some paraffin-embedded for histology, others snap-frozen to analyze eNOS, Arginase I–II expression, and activity. Results In CDH-bearing offsprings, ABH or Sildenafil+ABH preserved the total lung/body-weight index (p < 0.001), preventing pulmonary vascular smooth muscle cell hyperproliferation and improving lung morphometry. Sildenafil+ABH increased 1.7-fold the lung nitrite levels (p < 0.01) without changes in eNOS expression. Sildenafil and ABH improved the number of pulmonary vessels. Conclusion These results suggest that in this CDH rat model, the basal activity of Arginase participates in the lung volume and, together with phosphodiesterase-5, regulates NOS activity in the term fetal lung. The combined treatment (Sildenafil+ABH) could revert some of the pulmonary features in CDH by improving the local NO synthesis and preventing smooth muscle cell hyperproliferation. Impact This study presents Arginase inhibition as a new therapeutic target and the importance of the combined antenatal treatment to improve pulmonary vascular development in a congenital diaphragmatic hernia (CDH) rat model. This study shows that the action of an Arginase inhibitor (ABH) enhances the effects already described for sildenafil in this model. These results reinforce the importance of prenatal treatments’ synergy in recovering the hypoplastic lung in the Nitrofen-induced CDH rat model.
- 23 November 2022
- Published by Springer Nature in Pediatric Research
- Vol. 95 (4) , 941-948
Open AccessCongenital diaphragmatic hernia: phosphodiesterase-5 and Arginase inhibitors prevent pulmonary vascular hypoplasia in rat lungs
Background Severe pulmonary hypoplasia related to congenital diaphragmatic hernia (CDH) continues to be a potentially fatal condition despite advanced postnatal management strategies. Objective To evaluate the effect of the antenatal sildenafil and 2(S)-amino-6-boronohexanoic acid (ABH-Arginase inhibitor) on lung volume, pulmonary vascular development, and nitric oxide (NO) synthesis in a Nitrofen-induced CDH rat model. Methods Nitrofen-induced CDH rat model was used. Nitrofen was administrated on embryonic day(E) 9,5. At E14, five intervention groups were treated separately: Nitrofen, Nitrofen+Sildenafil, Nitrofen+ABH, Nitrofen+Sildenafil+ABH and Control. At term, offspring’s lungs were weighed, some paraffin-embedded for histology, others snap-frozen to analyze eNOS, Arginase I–II expression, and activity. Results In CDH-bearing offsprings, ABH or Sildenafil+ABH preserved the total lung/body-weight index (p < 0.001), preventing pulmonary vascular smooth muscle cell hyperproliferation and improving lung morphometry. Sildenafil+ABH increased 1.7-fold the lung nitrite levels (p < 0.01) without changes in eNOS expression. Sildenafil and ABH improved the number of pulmonary vessels. Conclusion These results suggest that in this CDH rat model, the basal activity of Arginase participates in the lung volume and, together with phosphodiesterase-5, regulates NOS activity in the term fetal lung. The combined treatment (Sildenafil+ABH) could revert some of the pulmonary features in CDH by improving the local NO synthesis and preventing smooth muscle cell hyperproliferation. Impact This study presents Arginase inhibition as a new therapeutic target and the importance of the combined antenatal treatment to improve pulmonary vascular development in a congenital diaphragmatic hernia (CDH) rat model. This study shows that the action of an Arginase inhibitor (ABH) enhances the effects already described for sildenafil in this model. These results reinforce the importance of prenatal treatments’ synergy in recovering the hypoplastic lung in the Nitrofen-induced CDH rat model.